Small Cell Lung Cancer Pipeline Analysis: 100+ Companies are Working to Improve the Treatment Space | DelveInsight

 Breaking News
  • No posts were found

Small Cell Lung Cancer Pipeline Analysis: 100+ Companies are Working to Improve the Treatment Space | DelveInsight

October 12
21:48 2022
Small Cell Lung Cancer Pipeline Analysis: 100+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight’s, “Small Cell Lung Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Small Cell Lung Cancer Pipeline Report

  • DelveInsight’s Small Cell Lung Cancer Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Small Cell Lung Cancer treatment.
  • The leading Small Cell Lung Cancer Companies includes Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Aileron Therapeutics, Ipsen, Celgene, Lee’s Pharmaceutical Limited, AbbVie, Chipscreen Biosciences, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, Amgen, Bristol-Myers Squibb, Genentech, Sorrento Therapeutics, DAIICHI SANKYO COMPANY, BioNTech, Harpoon Therapeutics, Genprex, Inc., Tarveda Therapeutics, Taizhou HoudeAoke Biomedical Co., Ltd., BeiGene, HaiHe Biopharma, Kartos Therapeutics, Inc., Boehringer Ingelheim, Y-mAbs Therapeutics, CStone Pharmaceuticals, EpicentRx, Inc., Pfizer, Mologen,  Cybrexa Therapeutics, and many others.
  • The promising Small Cell Lung Cancer therapies includes APG-1252, SYHA 1807, BNT 411, BMS 986012, LY 2510924, Serplulimab, Tiragolumab, Socazolimab, DS-7300, ABBV-011, HPN328, REQORSA, PEN-221, Gimatecan, LP002, LY01610, PLM60,  Ociperlimab, KRT-232, BI 764532, Nivatrotamab, CS1001, RRx-001, PF-06821497, CC-90011, AL3810, Lefitolimod, ALRN-6924,   CBX-12, and others are under development in different phases of clinical trials.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Small Cell Lung Cancer.

 

Get an overview of the Small Cell Lung Cancer Pipeline landscape @ Small Cell Lung Cancer Pipeline Outlook

 

Small Cell Lung Cancer Overview

Small cell lung cancer is fast-growing lung cancer that develops in the tissues of the lungs. It is the least common type of lung cancer and characterized by rapid, uncontrolled growth of certain cells in the lungs. Small cell lung cancer (SCLC), previously known as oat cell carcinoma, is considered distinct from other lung cancers, which are called non–small cell lung cancers (NSCLCs) because of their clinical and biologic characteristics. Small cell lung carcinoma (SCLC) arises in peribronchial locations and infiltrates the bronchial submucosa. Symptoms of SCLC are chest pain, chronic cough, coughing up blood, difficulty breathing, facial swelling, fatigue, hoarseness, loss of appetite, swollen neck veins, weight loss, and wheezing. The standard treatment for first- and second-line management of small cell lung cancer (SCLC) is chemotherapy. Immunotherapy has also made progress in the treatment of SCLC including nivolumab, pembrolizumab, atezolizumab, and durvalumab.

 

Latest Breakthroughs and Developments in the Small Cell Lung Cancer Treatment Landscape

  • In March 2022, Luye Pharma Group announced that it has filed a New Drug Application (NDA) in Hong Kong, China for Lurbinectedin, for the treatment of adult patients with metastatic Small-cell Lung Cancer (SCLC) with disease progression on or after receiving platinum-based chemotherapy. Lurbinectedin is an innovative oncology drug licensed to Luye Pharma by PharmaMar.
  • In March 2022, Harpoon Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN328, a delta-like ligand 3- (DLL3) targeting TriTAC®, for the treatment of Small-cell Lung Cancer (SCLC). A Phase 1/2 clinical trial is currently ongoing for HPN328 in the SCLC patient population. 
  • In March 2022, Akeso, Inc. announced that it has entered into a collaboration agreement with Shenzhen Chipscreen Biosciences, Ltd. (SHA Code 688321) to conduct a Phase Ib/II clinical study of combination therapy of Cadonilimab (PD-1/CTLA-4 bispecific antibody, AK104) and Chiauranib (a highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor) in patients with ES-SCLC which progressed on combination therapy of platinum-based chemotherapy and PD-(L)1 inhibitor as first-line treatment.
  • In March 2022, Shanghai Henlius Biotech, Inc., announced that the investigational new drug application (IND) of an international multicenter phase 3 studies of HANSIZHUANG (serplulimab), an innovative anti-PD-1 monoclonal antibody (mAb) independently developed by the Company, in combination with chemotherapy and concurrent radiotherapy in patients with limited-stage Small-Cell Lung Cancer (LS-SCLC) has been approved by the National Medical Products Administration (NMPA). Previously, the global multi-center phase 3 study of HANSIZHUANG for the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) has met the primary study endpoint of the overall survival (OS), and its NDA in China and MAA in the EU are expected to be filed in 2022, making HANSIZHUANG potentially the world’s first PD-1 inhibitor for the first-line treatment of SCLC.
  • In January 2022, Genprex, Inc. announced that it has expanded its oncology research and development pipeline to include Small-cell Lung Cancer (SCLC) as an additional disease indication for its lead drug candidate, REQORSA™ Immunogene Therapy.  
  • In December 2021, Shanghai Henlius Biotech, Inc. announced that the first interim analysis met the primary study endpoint of the overall survival (OS) of Phase 3 clinical study (NCT04063163) of its innovative PD-1 inhibitor serplulimab in combination with chemotherapy in previously untreated patients with extensive-stage small-cell lung cancer (ES-SCLC). There is no anti-PD-1 mAb approved for the treatment of extensive-stage small-cell lung cancer (ES-SCLC) worldwide.

 

Small Cell Lung Cancer Emerging Drugs

  • AMG 757: Amgen
  • APG-1252: Ascentage Pharma

 

Get to know more information about Small Cell Lung Cancer treatment therapies @ Small Cell Lung Cancer Clinical Trials

 

Small Cell Lung Cancer Pipeline Therapeutics Analysis

There are approx. 100+ key companies which are developing the therapies for Small Cell Lung Cancer. The companies which have their Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. Phase III include, Ipsen.

 

DelveInsight’s Small Cell Lung Cancer Pipeline Report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Discover more about therapy set to grab substantial Small Cell Lung Cancer Pipeline landscape @ Small Cell Lung Cancer Market Drivers and Barriers

 

Scope of the Small Cell Lung Cancer Pipeline Report

  • Coverage- Global
  • Small Cell Lung Cancer Companies- Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Aileron Therapeutics, Ipsen, Celgene, Lee’s Pharmaceutical Limited, AbbVie, Chipscreen Biosciences, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, Amgen, Bristol-Myers Squibb, Genentech, Sorrento Therapeutics, DAIICHI SANKYO COMPANY, BioNTech, Harpoon Therapeutics, Genprex, Inc., Tarveda Therapeutics, Taizhou HoudeAoke Biomedical Co., Ltd., BeiGene, HaiHe Biopharma, Kartos Therapeutics, Inc., Boehringer Ingelheim, Y-mAbs Therapeutics, CStone Pharmaceuticals, EpicentRx, Inc., Pfizer, Mologen,  Cybrexa Therapeutics, and others
  • Small Cell Lung Cancer Therapies- APG-1252, SYHA 1807, BNT 411, BMS 986012, LY 2510924, Serplulimab, Tiragolumab, Socazolimab, DS-7300, ABBV-011, HPN328, REQORSA, PEN-221, Gimatecan, LP002, LY01610, PLM60,  Ociperlimab, KRT-232, BI 764532, Nivatrotamab, CS1001, RRx-001, PF-06821497, CC-90011, AL3810, Lefitolimod, ALRN-6924,   CBX-12, and others
  • Small Cell Lung Cancer Therapeutic Assessment by Product Type
  • Small Cell Lung Cancer Therapeutic Assessment by Stage and Product Type
  • Small Cell Lung Cancer Therapeutic Assessment by Route of Administration
  • Small Cell Lung Cancer Therapeutic Assessment by Stage and Route of Administration
  • Small Cell Lung Cancer Therapeutic Assessment by Molecule Type
  • Small Cell Lung Cancer Therapeutic Assessment by Stage and Molecule Type
  • Small Cell Lung Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
  • Small Cell Lung Cancer – Market Drivers and Barriers

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Small Cell Lung Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Small Cell Lung Cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Pembrolizumab: Merck & Co
  11. Mid Stage Products (Phase II)
  12. Dostarlimab: GlaxoSmithKline
  13. Early Stage Products (Phase I)
  14. AMG 757: Amgen
  15. Preclinical/Discovery Stage Products
  16. S 055746: Vernalis
  17. Inactive Products
  18. Small Cell Lung Cancer Key Companies
  19. Small Cell Lung Cancer Key Products
  20. Small Cell Lung Cancer- Unmet Needs
  21. Small Cell Lung Cancer- Market Drivers and Barriers
  22. Small Cell Lung Cancer- Future Perspectives and Conclusion
  23. Small Cell Lung Cancer Analyst Views
  24. Small Cell Lung Cancer Key Companies
  25. Appendix

 

Got Queries? Reach out for more information on the Small Cell Lung Cancer Pipeline Report @ Small Cell Lung Cancer Pipeline Therapeutic Assessment

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Categories